Skip to main content

Advertisement

SpringerLink
Log in

Gemcitabine monotherapy in patients with heavily treated nasopharyngeal cancer: a case series

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Although gemcitabine is thought to play a critical role in the treatment of nasopharyngeal cancer, no research to evaluate the efficacy and toxicity of gemcitabine monotherapy has been conducted in Japan.

Methods

We retrospectively reviewed eight nasopharyngeal carcinoma patients treated with gemcitabine monotherapy at National Cancer Center Hospital East between May 2015 and August 2016. The main eligibility criteria were (1) histopathologically proven NPC; (2) tumor recurrence or an initial M1 TNM stage diagnosis; (3) at least two other types of systemic chemotherapy prior to gemcitabine; (4) no other active malignant tumor during treatment.

Results

All patients were administered gemcitabine 800–1000 mg/m2 on days 1, 8, and 15, repeated every 4 weeks. Gemcitabine was given as third-line systemic chemotherapy in six (74%) patients, as fourth-line in one (13%) and as fifth-line in one (13%). One patient had a complete response and one had a partial response, giving an overall response rate of 25%; four patients (50%) had stable disease and two (25%) experienced disease progression. The main toxicity was myelosuppression, with grade 3 leukopenia in three (38%) patients and neutropenia in four (50%). There were no treatment-related deaths. Median dose intensity and relative dose intensity of gemcitabine were 620 mg/m2/week and 97.5%, respectively.

Conclusion

Our findings suggest that GEM monotherapy is well tolerated and has potential as an active agent in Japanese patients with recurrent/metastatic NPC who have been heavily pretreated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386

    Article  CAS  PubMed  Google Scholar 

  2. Jin Y, Shi YX, Cai XY et al (2012) Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin 138:1717–1725

    Article  CAS  Google Scholar 

  3. Chua DTT, Yiu HHY, Seetalarom K et al (2012) Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer. Head Neck 34:1225–1230

    Article  PubMed  Google Scholar 

  4. Tan EH, Khoo KS, Wee J et al (1990) Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 10:235–237

    Article  CAS  Google Scholar 

  5. Ngeow J, Lim WT, Leong SS et al (2011) Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. Ann Oncol 22:718–722

    Article  CAS  PubMed  Google Scholar 

  6. Poon D, Chowbay B, Cheung YB et al (2005) Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma. Cancer 103:576–581

  7. Chua DTT, Sham JST, Au GKH et al (2003) A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol 39:361–366

    Article  CAS  PubMed  Google Scholar 

  8. Catimel G, Vermorken JB, Clavel M et al (1994) A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 5:543–547

  9. Zhang L, Huang Y, Hong S et al (2016) Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet 388:1883-1892

  10. Foo KF, Tan EH, Leong SS et al (2002) Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol 13:150–156

    Article  CAS  PubMed  Google Scholar 

  11. Zhang L, Zhang Y, Huang PY et al (2008) Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. Cancer Chemoth Pharm 61:33–38

    Article  CAS  Google Scholar 

  12. Sobin LH, Gospodarowicz MK, Wittekind CH (2009) UICC TNM classification of malignant tumours, 7th edn. Wiley, New York

    Google Scholar 

  13. Kaidar-Person O, Kuten J, Atrash F et al (2012) Brain metastasis of nasopharyngeal carcinoma: a case report and literature review. Case Rep Med 2012:405917

    Article  PubMed  PubMed Central  Google Scholar 

  14. Sarmiento JM, Wi MS, Piao Z et al (2012) Solitary cerebral metastasis from transitional cell carcinoma after a 14-year remission of urinary bladder cancer treated with gemcitabine: case report and literature review. Surg Neurol Int 3:82

    Article  PubMed  PubMed Central  Google Scholar 

  15. Crino L, Mosconi AM, Scagliotti G et al (1999) Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 17:2081–2085

    Article  CAS  PubMed  Google Scholar 

  16. Lee HW, Hwang YH, Han JH et al (2010) High expression of excision repair cross-complementation group1 protein predicts poor outcome in patients with nasopharyngeal cancer. Oral Oncol 46:209–213

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank all the members of staff at National Cancer Center Japan.

Author information

Author notes

  1. Makoto Tahara

    Present address: Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan

Authors and Affiliations

  1. Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan

    Tomohiro Enokida, Takao Fujisawa, Yuri Ueda & Susumu Okano

  2. Division of Pharmacy, National Cancer Center Hospital East, Kashiwa, Chiba, Japan

    Shinya Uozumi

Authors
  1. Tomohiro Enokida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shinya Uozumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takao Fujisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuri Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Susumu Okano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Makoto Tahara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Makoto Tahara.

Ethics declarations

Conflict of interest

The authors report no conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Enokida, T., Uozumi, S., Fujisawa, T. et al. Gemcitabine monotherapy in patients with heavily treated nasopharyngeal cancer: a case series. Int J Clin Oncol 22, 1009–1014 (2017). https://doi.org/10.1007/s10147-017-1152-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-017-1152-8

Keywords

Search

Navigation